Titre :

Rapid Push vs Pump-Infused Subcutaneous Immunoglobulin Treatment: a Randomized Crossover Study of Quality of Life in Primary Immunodeficiency Patients.

Auteur(s) :

Bienvenu, Boris [Auteur]
Cozon, Gregoire [Auteur]
Mataix, Yves [Auteur]
Lachaud, Dominique [Auteur]
Alix, Antoine [Auteur]
Hoarau, Cyrille [Auteur]
Antier, Daniel [Auteur]
Hachulla, Eric [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Brice, Sylvie [Auteur]
Viallard, Jean-Francois [Auteur]
Tamisier, Stephanie [Auteur]
Fauchais, Anne-Laure [Auteur]
Renon-Carron, Francoise [Auteur]
Clerson, Pierre [Auteur]
Impact de l'environnement chimique sur la santé humaine - ULR 4483 [IMPECS]
Fardini, Yann [Auteur]
Crave, Jean-Charles [Auteur]
Miossec, Pierre [Auteur]

Titre de la revue :

Journal of Clinical Immunology

Nom court de la revue :

J. Clin. Immunol.

Numéro :

38

Pagination :

503–512

Date de publication :

2018-05

ISSN :

1573-2592

Mot(s)-clé(s) :

Primary immunodeficiency
PID immunoglobulin replacement therapy
home treatment
rapid push

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Purpose: Subcutaneous immunoglobulin replacement therapy (IgRT) may be administered once a week with a pump or every other day with a syringe (rapid push). The objective of the study was to compare the impact of pump and ...
Lire la suite >Purpose: Subcutaneous immunoglobulin replacement therapy (IgRT) may be administered once a week with a pump or every other day with a syringe (rapid push). The objective of the study was to compare the impact of pump and rapid push infusions on patient’s life quality index (LQI). Methods: This study was a randomized, crossover, multicenter, non-inferiority trial conducted in adults with primary immunodeficiency (PID) accustomed to weekly infusions at home by pump. Patients used pump or rapid push for 3 months each according to the randomized sequence. Main criterion was PID-LQI factor I (treatment interference). Non-inferiority ratio was set at 90%. Results: Thirty patients entered the study; 28 completed the two periods. IgRT exposure was similar during each period. At the end of each period, mean LQI factor 1 was 87.0 (IC95% [80.3; 94.3]) and 77.80 (IC95% [71.5; 84.7]) for pump and rapid push, respectively. There was a slightly larger effect of rapid push on treatment interference than with pump so that the primary endpoint could not be met. No difference was found on other LQI components, satisfaction (TSQM), or quality of life (SF36v2). Eight patients declared to prefer rapid push while 19 others preferred pump. Of rapid push infusions, 67.2% led to local reactions vs 71.8% of pump infusions (p = 0.11) illustrating its good tolerance. Rapid push and pump infusions achieved similar trough IgG levels with similar incidence of infections. Rapid push saved 70% of administration cost when compared to pump. Conclusions: Since IgRT is a lifelong treatment in PID patients, individualization of treatment is of paramount importance. Rapid push is a new administration method in the physician’s armamentarium which is preferred by some patients and is cost-effective.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Inserm
Université de Lille
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Équipe(s) de recherche :

Immunity, inflammation and fibrsis in auto and allo-reactivity

Date de dépôt :

2019-03-01T14:35:29Z
2023-11-29T14:28:56Z